# Orthofix Medical Inc.: Form 10-Q for the period ended Mar 31, 2023

- Company: [Orthofix Medical Inc.](/companies/ofix.md) (CIK 884624)
- Form: 10-Q
- Filed: 2023-05-09
- Accepted by EDGAR: May 9, 2023, 16:21 ET
- Period: 2023-03-31
- Accession: 0000950170-23-019721
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/884624/000095017023019721/ofix-20230331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/884624/000095017023019721/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $175.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $64.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $110.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $23.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | −$59.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $611.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | −$60.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | −$1.71 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | −$1.71 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 35,734 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | −$34.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-01-01 to 2023-03-31 | $11.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-03-31 | $50.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $410.0m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $917.1m | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $137.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $253.0m | us-gaap:Liabilities |
| Long-term debt | at 2023-03-31 | $45.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2023-03-31 | $664.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 26,147 characters.

The following discussion and analysis of Orthofix Medical Inc.’s (sometimes referred to as “we,” “us” or “our”) financial condition and results of operations should be read in conjunction with the discussion under the heading “Forward-Looking Statements” and our condensed consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-Q.

### Executive Summary

Following our recent merger (the “Merger”) with SeaSpine Holdings Corporation ("SeaSpine"), the newly merged Orthofix-SeaSpine organization is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Headquartered in Lewisville, Texas, our spine and orthopedic products are distributed in approximately 68 countries via our sales representatives and distributors. For more information, please visit www.Orthofix.com. Information included on our website is not incorporated into, or otherwise creates a part of, this report.

Notable financial metrics in the first quarter of 2023 and recent achievements include the following:

- Net sales of $175.2 million, an increase of 65% on a reported basis and 66% on a constant currency basis over prior year
- Global Spine net sales growth of 81% on both a reported basis and constant currency basis, driven largely by the Merger, coupled with organic growth from our Bone Growth Therapies and Spinal Implants product categories
- Global Orthopedics net sales growth of 9% on a reported basis and 14% on a constant currency basis, with growth observed in both the U.S. and international markets
- Announced the full commercial launch of the Lattus Lateral Access System and the Fathom Pedicle-Based Retractor System, which addresses an estimated $1.8 billion market related to minimally invasive spine procedures

### Results of Operations

The following table provides certain items in our condensed consolidated statements of operations as a percent of net sales:

*(Unaudited)*

|  | Three Months Ended March 31, 2023 (%) | 2022 (%) |
| --- | ---: | ---: |
| Net sales | 100.0 | 100.0 |
| Cost of sales | 37.0 | 26.6 |
| Gross profit | 63.0 | 73.4 |
| Sales and marketing | 53.5 | 50.9 |
| General and administrative | 27.9 | 18.2 |
| Research and development | 13.3 | 10.5 |
| Acquisition-related amortization and remeasurement | 2.4 | (3.3) |
| Operating income (loss) | (34.1) | (2.9) |
| Net loss | (34.8) | (4.2) |

### Net Sales by Product Category and Reporting Segment

The following tables provide net sales by major product category by reporting segment:

*(Unaudited, U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | Percentage Change Reported | Constant Currency |
| --- | ---: | ---: | ---: | ---: |
| Bone Growth Therapies | $47,714 | $41,948 | 13.7% | 13.7% |
| Spinal Implants and Enabling Technologies | 60,862 | 26,615 | 128.7% | 129.1% |
| Biologics | 40,630 | 14,092 | 188.3% | 188.2% |
| Global Spine | 149,206 | 82,655 | 80.5% | 80.6% |
| Global Orthopedics | 25,998 | 23,763 | 9.4% | 13.6% |
| Net sales | $175,204 | $106,418 | 64.6% | 65.7% |

20

Global Spine

Global Spine offers the following product categories:

- Bone Growth Therapies, which manufactures, distributes, sells, and provides support services for market leading devices used adjunctively in high risk spinal fusion procedures and to treat both non-union and acute fractures in the orthopedic space. Bone Growth Therapies uses distributors and a direct sales channel to sell its devices and provide associated support services to hospitals, healthcare providers, and patients.
- Spinal Implants and Enabling Technologies, which designs, develops, and markets a broad portfolio of spine fixation and motion preservation implant products used in surgical procedures of the spine. The portfolio also consists of image-guided surgical solutions to facilitate degenerative, minimally invasive, and complex surgical procedures. Spinal Implants and Enabling Technologies distributes its products globally through a network of distributors and sales representatives to sell spine products to hospitals and healthcare providers.
- Biologics, which provides a portfolio of advanced and traditional bone graft substitutes designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. Biologics markets its tissues to hospitals and healthcare providers, primarily in the U.S., through a network of employed and independent sales representatives.

#### Three months ended March 31, 2023 compared to 2022

Net sales of $149.2 million, an increase of $66.6 million or 80.5%

- Bone Growth Therapies net sales increased $5.8 million or 13.7%, largely driven by an increase in complex spine procedures, which are typically paired within our CervicalStim and SpinalStim devices, and growth in our fracture sales channel as a result of investments made in the commercial channel in the prior year, as well as the launch of AccelStim for the healing fresh and non-union fractures
- Spinal Implants and Enabling Technologies net sales increased $34.2 million or 128.7%, primarily due to the contribution of SeaSpine net sales in the first quarter of 2023 in addition to growth driven by the onboarding of new, high-volume distribution partners along with multiple new product launches
- Biologics net sales increased $26.5 million or 188.3%, largely driven by the contribution of SeaSpine net sales in the first quarter of 2023 in addition to growth driven by the onboarding of new distribution partners in the U.S. as we are now able to provide one of the most comprehensive biologics portfolios in both the demineralized bone matrix and cellular allograft product categories as a result of the Merger

Global Orthopedics

Global Orthopedics offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions specifically related to limb reconstruction and deformity correction unrelated to the spine. Global Orthopedics distributes its products globally through a network of distributors and sales representatives to sell orthopedic products to hospitals and healthcare providers.

#### Three months ended March 31, 2023 compared to 2022

Net sales of $26.0 million, an increase of $2.2 million or 9.4%

- Double-digit growth in the U.S. and internationally, on a constant currency basis, largely as a result of investments made in new product launches and commercial execution within our U.S. sales channel and from an increase in international stocking distributor orders
- Partially offset by a decrease of $1.0 million due to movement in foreign currency exchange rates

### Gross Profit

*(Unaudited, U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: |
| Net sales | $175,204 | $106,418 | 64.6% |
| Cost of sales | 64,875 | 28,318 | 129.1% |
| Gross profit | $110,329 | $78,100 | 41.3% |
| Gross margin | 63.0% | 73.4% | (10.4%) |

#### Three months ended March 31, 2023 compared to 2022

Gross profit increased $32.2 million

- Gross profit largely increased due to the contribution of SeaSpine results in the first quarter of 2023, as SeaSpine contributed approximately $60.9 million net sales
- Partially offset by $11.6 million in amortization of the inventory fair value step up at acquisition, which is being recognized over the expected sales cycles of the acquired inventory
- Further offset by approximately $0.7 million in inventory-related charges as a result of product rationalization decisions that have been made related to the Merger

### Sales and Marketing Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: |
| Sales and marketing | $93,791 | $54,137 | 73.2% |
| As a percentage of net sales | 53.5% | 50.9% | 2.6% |

#### Three months ended March 31, 2023 compared to 2022

Sales and marketing expense increased $39.7 million

- Increase largely due to the contribution of SeaSpine results in the first quarter of 2023 and the overall increase in net sales as compared to the prior year period, which resulted in increased variable expenses, such as commissions and bonus expenses associated with the achievement of sales objectives
- Included within sales and marketing expenses for the first quarter of 2023 are integration-related expenses of $1.9 million, which are mainly comprised of severance and retention costs

### General and Administrative Expense

*(U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: |
| General and administrative | $48,811 | $19,328 | 152.5% |
| As a percentage of net sales | 27.9% | 18.2% | 9.7% |

22

#### Three months ended March 31, 2023 compared to 2022

General and administrative expense increased $29.5 million

- Increase largely due to the contribution of SeaSpine results in the first quarter of 2023 and resulting integration costs incurred as a result of the Merger
- Included within general and administrative expenses for the first quarter of 2023 are merger and integration-related expenses of $17.3 million, which are mainly comprised of (i) professional fees totaling $9.8 million, inclusive of a $5.5 million payment to Orthofix's financial advisor for the Merger upon closing of the transaction, and (ii) severance and retention costs totaling $7.0 million
- Increase also driven by $5.9 million in higher share-based compensation expense as a result of a larger employee base post-Merger and from accelerated vesting of certain equity-based awards as a result of the Merger

### Research and Development Expense

*(Unaudited, U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: |
| Research and development | $23,307 | $11,212 | 107.9% |
| As a percentage of net sales | 13.3% | 10.5% | 2.8% |

#### Three months ended March 31, 2023 compared to 2022

Research and development expense increased $12.1 million

- Increase largely due to the contribution of SeaSpine results in the first quarter of 2023 and resulting integration costs incurred as a result of the Merger
- Included within research and development expenses for the first quarter of 2023 are merger and integration-related expenses of $1.6 million, which are mainly comprised of severance and retention costs
- Increase of $1.0 million related to our European Union medical device regulation implementation efforts
- Increase of $0.8 million related to the attainment of a development milestone with MTF Biologics achieved in the first quarter of 2023

### Acquisition-related Amortization and Remeasurement

*(Unaudited, U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: |
| Acquisition-related amortization and remeasurement | $4,134 | $(3,499) | (218.1%) |
| As a percentage of net sales | 2.4% | (3.3%) | 5.7% |

Acquisition-related amortization and remeasurement consists of (i) amortization related to intangible assets acquired through business combinations or asset acquisitions, (ii) remeasurement of any related contingent consideration arrangement, and (iii) costs associated with acquired in-process research and development assets, which are recognized immediately upon acquisition.

#### Three months ended March 31, 2023 compared to 2022

Acquisition-related amortization and remeasurement increased $7.6 million

- Increase of $5.5 million related to a benefit recognized in the first quarter of 2022 from the remeasurement of potential revenue-based milestone payments associated with the Spinal Kinetics acquisition; we did not achieve the remaining milestone prior to April 30, 2023, the end of the measurement period for achieving such milestone
- Increase in amortization expense of $2.1 million during the first quarter of 2023 associated with intangible assets recognized as a result of the Merger

### Non-operating Income and Expense

*(Unaudited, U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: |
| Interest expense, net | $(1,289) | $(375) | 243.7% |
| Other expense, net | 676 | (936) | (172.2%) |

23

#### Three months ended March 31, 2023 compared to 2022

Interest expense, net increased $0.9 million

- Increase of $0.6 million attributable to an early termination prepayment penalty associated with the payoff of the assumed indebtedness of SeaSpine as of the close of the Merger
- Increase of $0.5 million attributable to an increase in borrowings outstanding on our secured revolving credit facility in the first quarter of 2023 as no such balance was outstanding in the prior year

#### Three months ended March 31, 2023 compared to 2022

Other income (expense), net increased $1.6 million

- Increase of $1.8 million associated with changes in foreign currency exchange rates, as we recorded a non-cash remeasurement gain of $0.6 million in 2023 compared to a loss of $1.2 million in 2022

### Income Taxes

*(Unaudited, U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | % Change |
| --- | ---: | ---: | ---: |
| Income tax expense | $611 | $71 | 760.6% |
| Effective tax rate | (1.0%) | (1.6%) | 0.6% |

#### Three months ended March 31, 2023 compared to 2022

- The increase in tax expense compared to the prior year period was primarily a result of changes in valuation allowances
- The primary factors affecting our tax expense for the first quarter of 2023 were financial statement losses not benefitted

### Segment Review

Our business is managed through two reporting segments: Global Spine and Global Orthopedics. The primary metric used in managing the business by segment is adjusted earnings before interest, tax, depreciation, and amortization (“Adjusted EBITDA”) (which is described further in Note 11 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein). The following table presents adjusted EBITDA by segment and reconciles consolidated adjusted EBITDA to loss before income taxes:

*(Unaudited, U.S. Dollars, in thousands)*

| Adjusted EBITDA by reporting segment | Three Months Ended March 31, 2023 | 2022 |
| --- | ---: | ---: |
| Global Spine | 14,981 | 14,033 |
| Global Orthopedics | 44 | (804) |
| Corporate | (11,821) | (6,120) |
| **Consolidated adjusted EBITDA** | $3,204 | $7,109 |
| Reconciling items: |  |  |
| Interest expense, net | 1,289 | 375 |
| Depreciation and amortization | 12,670 | 7,516 |
| Share-based compensation expense | 13,020 | 4,332 |
| Foreign exchange impact | (583) | 1,242 |
| SeaSpine merger-related costs | 20,740 | — |
| Strategic investments | 661 | 970 |
| Acquisition-related fair value adjustments | 11,636 | (5,500) |
| Legal judgments/settlements | 469 | 193 |
| Medical device regulation | 3,629 | 1,952 |
| Business interruption - COVID-19 | — | 343 |
| All other | — | 75 |
| **Loss before income taxes** | $(60,327) | $(4,389) |

24

### Liquidity and Capital Resources

Cash and cash equivalents at March 31, 2023, totaled $50.0 million compared to $50.7 million at December 31, 2022.

*(Unaudited, U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | Change |
| --- | ---: | ---: | ---: |
| Net cash from operating activities | $(34,020) | $(7,709) | $(26,311) |
| Net cash from investing activities | 17,084 | (5,667) | 22,751 |
| Net cash from financing activities | 15,983 | (2,233) | 18,216 |
| Effect of exchange rate changes on cash | 221 | (321) | 542 |
| Net change in cash and cash equivalents | $(732) | $(15,930) | $15,198 |

The following table presents free cash flow, a non-GAAP financial measure, which is calculated by subtracting capital expenditures from net cash from operating activities:

*(Unaudited, U.S. Dollars, in thousands)*

|  | Three Months Ended March 31, 2023 | 2022 | Change |
| --- | ---: | ---: | ---: |
| Net cash from operating activities | $(34,020) | $(7,709) | $(26,311) |
| Capital expenditures | (11,835) | (5,667) | (6,168) |
| Free cash flow | $(45,855) | $(13,376) | $(32,479) |

### Operating Activities

Cash flows from operating activities decreased $26.3 million

- Unfavorable change in net loss of $56.5 million
- Favorable change of $35.9 million associated with non-cash gains and losses, largely related the amortization of the inventory fair value step up at acquisition, share-based compensation expense, changes in fair value of contingent consideration, inventory reserve expenses, depreciation and amortization
- Unfavorable change of $5.7 million relating to changes in working capital accounts, primarily attributable to changes in inventory levels, partially offset by recoupment activity associated with the CMS Accelerated and Advance Payment Program in the prior year

Two of our primary working capital accounts are accounts receivable and inventory. Days sales in receivables were 58 days at March 31, 2023, compared to 61 days at March 31, 2022. Inventory turns decreased to 0.7 times as of March 31, 2023 compared to 1.3 times as of March 31, 2022.

### Investing Activities

Cash flows from investing activities increased $22.8 million

- Increase of $29.4 million attributable to cash acquired as a result of the Merger
- Partially offset by an increase of $6.1 million in capital expenditures, largely due to the inclusion of SeaSpine within the first quarter of 2023 operating results

### Financing Activities

Cash flows from financing activities increased $18.2 million

- Increase of $45.0 million associated with borrowings under our secured revolving credit facility for working capital purposes, including to fund certain Merger-related expense, during the first quarter of 2023
- Increase of $2.0 million related to the conclusion of the FITBONE Contract Manufacturing and Supply Agreement with Wittenstein, resulting in a $2.0 million payment in the first quarter of 2022
- Partially offset by a decrease of $26.9 million associated with the termination and repayment of SeaSpine's credit facility
- Further offset by a decrease in net proceeds of $1.9 million from the issuance of common shares, primarily related the payment of tax withholding obligations for share-based compensation arrangements

#### Credit Facilities

On January 3, 2023, we borrowed $30.0 million under our $300.0 million secured revolving credit facility for working capital purposes, including to fund certain Merger-related expenses. Following the completion of the Merger, we terminated SeaSpine's credit facility and all applicable commitments with Wells Fargo Bank, National Association and repaid all outstanding obligations in respect to principal, interest, and fees on January 5, 2023.

In addition, we borrowed $15.0 million under our secured revolving credit facility on March 3, 2023, thus, as of March 31, 2023, we had $45.0 million borrowings outstanding under our secured revolving credit facility. In addition, we had no borrowings outstanding under our available lines of credit in Italy, which provide up to an aggregate amount of €5.5 million ($6.0 million). We were in compliance with all required financial covenants of our credit facilities as of March 31, 2023.

### Other

For information regarding contingencies, see Note 8 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.

#### IGEA S.p.A Exclusive License and Distribution Agreement

In April 2021, we entered into an Exclusive License and Distribution Agreement (the “License Agreement”) with IGEA S.p.A (“IGEA”), an Italian manufacturer and distributor of bone and cartilage stimulation systems. Per the terms of the License Agreement, we have the exclusive right to sell IGEA products in the U.S. and Canada. As consideration for the License Agreement, we agreed to pay up to $4.0 million, with certain payments contingent upon achieving an FDA milestone. As of March 31, 2023, we have remaining liabilities under this agreement of $2.0 million which have been accrued in full within other current and long-term liabilities.

#### CGBio Co., Ltd. Exclusive License and Distribution Agreement

On July 30, 2022, we entered into a long-term strategic License and Distribution Agreement (the “Agreement”) with CGBio Co., Ltd. (“CGBio”), a developer of innovative, synthetic bone grafts. The agreement grants us the exclusive right to conduct pre-clinical and clinical studies, commercialize, promote, market, and sell the Novosis recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials and other future tissue regenerative solutions in the U.S. and Canada. As consideration, we paid CGBio an upfront payment of $1.4 million with additional payments contingent upon the achievement of specified development milestones.

#### Lattus Spine LLC ("Lattus") Contingent Consideration

In connection with the Merger, we assumed a contingent consideration obligation under a purchase agreement between SeaSpine and Lattus executed in December 2022. Under the terms of the agreement, we may be required to make installment payments at certain dates based on future net sales of certain products (the "Lateral Products"). The estimated fair value of the contingent consideration arrangement as of March 31, 2023, was $11.5 million; however, the actual amount ultimately paid could be higher or lower than the estimated fair value of the contingent consideration. As of March 31, 2023, we classified the remaining contingent consideration liability within other long-term liabilities. For additional discussion of this matter, see Note 7 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

### Off-balance Sheet Arrangements

As of March 31, 2023, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, cash flows, liquidity, capital expenditures or capital resources that are material to investors.

### Contractual Obligations

There have been no material changes in any of our material contractual obligations as disclosed in our Form 10-K for the year ended December 31, 2022.

### Critical Accounting Estimates

Our discussion of operating results is based upon the condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are described in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no significant changes to our critical accounting estimates during the quarter covered by this report.

### Recently Issued Accounting Pronouncements

See Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued or adopted accounting pronouncements.

### Non-GAAP Financial Measures

We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. We believe it is important to provide investors with the same non-GAAP financial measures used to supplement information regarding the performance and underlying trends of our business operations to facilitate comparisons to historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

The non-GAAP financial measures used in this filing may have limitations as analytical tools and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost that can have a material effect on cash flows.

#### Constant Currency

Constant currency is calculated by using foreign currency rates from the comparable, prior-year period to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

#### Adjusted EBITDA

EBITDA is a non-GAAP financial measure defined as earnings before interest income (expense), income taxes, depreciation, and amortization. Adjusted EBITDA is the primary metric used by our Chief Operating Decision Maker in managing the business. Adjusted EBITDA represents earnings before interest income (expense), income taxes, depreciation, and amortization and excludes the impact of: share-based compensation, gains and losses related to foreign currency translation, SeaSpine Merger-related costs, strategic investments, acquisition-related fair value adjustments, gains or losses recognized on investment securities, legal judgments and settlements, charges related to initial compliance with regulations set forth by the European Union Medical Device Regulation, and gains and losses related to the realized effects the COVID-19 pandemic has had on our business operations.

#### Free Cash Flow

Free cash flow is calculated by subtracting capital expenditures from net cash from operating activities. Management uses free cash flow as an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.

## Market risk

As filed, 123 characters.

There have been no material changes to our market risks as disclosed in our Form 10-K for the year ended December 31, 2022.

## Controls and procedures

As filed, 2,005 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. These include controls and procedures designed to ensure that this information is accumulated and communicated to management, including our President and Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Management, with the participation of the President and Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2023.

On January 5, 2023, the Company completed a merger of equals with SeaSpine, whose financial statements reflect total assets and revenues constituting 52% and 35%, respectively, of the condensed consolidated financial statement amounts as of and for the three months ended March 31, 2023. As permitted by the rules of the SEC, the Company will exclude SeaSpine from its annual assessment of the effectiveness on internal control over financial reporting for the year ending December 31, 2023, the year of acquisition. Management continue to monitor SeaSpine's internal controls over financial reporting.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,834 characters.

There have been no material changes from the risk factors disclosed in "Part I, Item 1A. Risk Factors” in our Form 10-K for the year ended December 31, 2022, except as follows.

*We hold our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institutions holding such funds fail.*

We hold our cash and cash equivalents used to meet our working capital and operating expense needs in deposit accounts at multiple financial institutions. The balance held in these accounts typically exceeds the Federal Deposit Insurance Corporation ("FDIC") standard deposit insurance limit or similar government guarantee schemes. If a financial institution in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of such uninsured funds. Any such loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations.

For example, on March 10, 2023, Silicon Valley Bank ("SVB"), and Signature Bank, were closed by state regulators and the FDIC was appointed receiver for each bank. The FDIC created successor bridge banks and all deposits of SVB and Signature Bank were transferred to the bridge banks under a systemic risk exception approved by the United States Department of Treasury, the Federal Reserve, and the FDIC. If financial institutions in which we hold funds for working capital and operating expenses were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits in a similar manner.

Filed May 9, 2023.
Source: SEC EDGAR, the filing index for accession 0000950170-23-019721. Last ingested by Listed: Nov 13, 2026, 17:00 ET. No prices; not investment advice.
